Edgewise Therapeutics’ treatment candidate for several forms of muscular dystrophy has hit the primary endpoint in a mid-stage study, setting in motion plans for regulatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.